Brazil’s public healthcare system, known as the Unified Health System or SUS, has entered a new era in the fight against rare diseases. The government now offers whole-exome sequencing — a complete DNA analysis — free of charge through its public network. This landmark step is transforming how doctors detect rare genetic conditions across the country. Furthermore, it signals a major shift in health equity for the millions of Brazilians who previously had no access to advanced genomic tools.
What Is Whole-Exome Sequencing?
Understanding the Technology
Whole-exome sequencing is an advanced form of genetic testing. It maps the protein-coding regions of a person’s DNA to identify mutations linked to rare or complex diseases. Unlike older diagnostic methods, this technology delivers highly accurate results — and it does so at a fraction of the cost of private testing.
Why It Matters for Rare Diseases
Rare diseases affect at least 13 million people in Brazil today. Historically, patients waited an average of seven years before receiving a confirmed diagnosis. Moreover, many families went without answers altogether. With whole-exome sequencing, Brazil aims to cut that wait time to just six months. Consequently, patients can access treatment sooner — and improve their quality of life much faster.
How the Test Works
A Simple Collection Process
The test begins with a simple, non-invasive procedure. A healthcare professional uses a cotton swab on the inside of the patient’s cheek to collect cells. Alternatively, doctors can use a blood sample if needed. After that, laboratories perform the complete DNA sequencing analysis. The process is straightforward, and patients experience minimal discomfort.
Who Can Access the Test?
Any patient seen at a referral center — or identified through neonatal screening — qualifies for the sequencing service. Therefore, newborns and children showing early signs of developmental delays or genetic conditions gain access quickly. In addition, patients with undiagnosed intellectual disabilities also benefit from this new tool.
Key Benefits for Patients and Doctors
Faster and More Accurate Diagnoses
Natan Monsores, the coordinator of rare diseases at Brazil’s Ministry of Health, described the technology as “a huge gain for the community of people with rare diseases.” He added that it gives geneticists, neurology teams, and pediatricians an essential tool to confirm complex diagnoses. As a result, medical teams now work with greater confidence and efficiency.
Advancing Children’s Health
Beyond general rare diseases, the test advances diagnosis of intellectual disabilities and a wide diversity of genetic conditions that affect children. This is particularly vital because rare genetic diseases remain a leading cause of childhood mortality globally. Early detection, therefore, directly improves survival rates and long-term health outcomes for young patients.
Investment and Government Commitment
Brazil’s Ministry of Health invested R$26 million in the first year to launch this technology within the SUS. This significant funding demonstrates the government’s commitment to expanding access to high-quality diagnostic care. Notably, providing this test through the public system means even low-income patients can benefit — without facing private laboratory costs.
Within just 90 days of launching the platform, labs completed 412 sequencing tests and identified 175 diagnostic findings. These early results prove the program’s effectiveness. Moreover, they build a strong foundation for scaling the service nationwide.
Expansion Goals Across Brazil
Current Reach
Currently, 11 Brazilian states have active sequencing services up and running. The platform handles up to 20,000 requests per year at this stage. While this represents a strong start, the government recognizes that demand far exceeds current capacity.
The April 2026 Target
The Ministry of Health has set a clear goal: expand the sequencing network to all Brazilian states by April 2026. This expansion will bring the technology to underserved regions where access to specialized genetic care has been extremely limited. Ultimately, the plan aims to eliminate geographic barriers and deliver equitable healthcare across Brazil’s vast territory.
Gene Therapy: A Complementary Breakthrough
In addition to whole-exome sequencing, Brazil’s Ministry of Health announced another major development. Children diagnosed with spinal muscular atrophy now have access to innovative gene therapy through the public system. This treatment targets the root genetic cause of the disease, rather than just managing its symptoms. Together, these two advances — sequencing and gene therapy — represent a powerful new approach to rare disease care within SUS.
Conclusion: A Healthier Future for Millions
Brazil’s introduction of whole-exome sequencing into the public healthcare system marks a turning point in rare disease management. The technology shortens diagnostic timelines from years to months, improves accuracy, and reduces costs. Furthermore, it brings advanced genomic medicine to millions of patients who previously had no access to it. As the program expands toward full national coverage by April 2026, Brazil positions itself as a global model for equitable healthcare innovation.
